[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY38767A - Compuestos para el tratamiento de enfermedades y trastornos asociados con braf - Google Patents

Compuestos para el tratamiento de enfermedades y trastornos asociados con braf

Info

Publication number
UY38767A
UY38767A UY0001038767A UY38767A UY38767A UY 38767 A UY38767 A UY 38767A UY 0001038767 A UY0001038767 A UY 0001038767A UY 38767 A UY38767 A UY 38767A UY 38767 A UY38767 A UY 38767A
Authority
UY
Uruguay
Prior art keywords
braf
compounds
treatment
diseases
disorders associated
Prior art date
Application number
UY0001038767A
Other languages
English (en)
Inventor
Patrick Michael Barbour
Katie Keaton Brown
Adam Wade Cook
Erik James Hicken
Dean Russell Kahn
Ellen Ruth Laird
Andrew Terrance Metcalf
David Austin Moreno
Bradley Jon Newhouse
Spencer Phillip Pajk
Brett Joseph Prigaro
Li Ren
Eugene Tarlton
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of UY38767A publication Critical patent/UY38767A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proveen compuestos de la fórmula I: y sales, solvatos y polimorfos farmacéuticamente aceptable de los mismos, en donde L, X1, R1, R2, R3, R4, R5 y R6 son como se define en la presente, para el tratamiento de enfermedades y trastornos asociados a BRAF, incluyendo tumores asociados a BRAF, incluyendo tumores malignos y benignos asociados a BRAF del SNC y tumores asociados a BRAF extracraneales malignos.
UY0001038767A 2019-06-28 2020-06-26 Compuestos para el tratamiento de enfermedades y trastornos asociados con braf UY38767A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962868581P 2019-06-28 2019-06-28
US202063021410P 2020-05-07 2020-05-07

Publications (1)

Publication Number Publication Date
UY38767A true UY38767A (es) 2021-01-29

Family

ID=71465389

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038767A UY38767A (es) 2019-06-28 2020-06-26 Compuestos para el tratamiento de enfermedades y trastornos asociados con braf

Country Status (20)

Country Link
US (2) US11414404B2 (es)
EP (1) EP3990437A1 (es)
JP (1) JP7169469B2 (es)
KR (1) KR102712548B1 (es)
CN (1) CN114026073B (es)
AU (1) AU2020302352B2 (es)
BR (1) BR112021025102A2 (es)
CA (1) CA3144859C (es)
CO (1) CO2021017438A2 (es)
CR (1) CR20210626A (es)
CU (1) CU20210098A7 (es)
EC (1) ECSP21093541A (es)
IL (1) IL288214B1 (es)
MA (1) MA56387A (es)
MX (1) MX2021015903A (es)
PE (1) PE20220341A1 (es)
TW (1) TWI817018B (es)
UY (1) UY38767A (es)
WO (1) WO2020261156A1 (es)
ZA (1) ZA202201329B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
EP4073044A1 (en) * 2019-12-10 2022-10-19 F. Hoffmann-La Roche AG New braf inhibitors as paradox breakers
JP7108146B2 (ja) 2019-12-10 2022-07-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規メチルキナゾリノン誘導体
JP7312335B2 (ja) 2020-06-09 2023-07-20 アレイ バイオファーマ インコーポレイテッド Ｂｒａｆ関連疾患および障害を処置するための４－オキソ－３，４－ジヒドロキナゾリノン化合物
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
IL307964A (en) * 2021-06-09 2023-12-01 Chugai Pharmaceutical Co Ltd Combined treatment for cancer
CN118201615A (zh) * 2021-11-04 2024-06-14 豪夫迈·罗氏有限公司 喹唑啉酮化合物用于治疗癌症的新用途
MX2024006771A (es) * 2021-12-08 2024-06-20 Array Biopharma Inc Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida.
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024054591A1 (en) * 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2024105144A1 (en) * 2022-11-18 2024-05-23 F. Hoffmann-La Roche Ag Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2335276T3 (es) 2002-03-13 2010-03-24 Array Biopharma, Inc. Derivados de bencimidazol alquilado n3 como inhibidores de mek.
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
WO2005051302A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1789399A1 (en) 2004-08-31 2007-05-30 AstraZeneca AB Quinazolinone derivatives and their use as b-raf inhibitors
SA06270141B1 (ar) 2005-05-18 2009-11-15 اراي بيوفارما انك مثبطات حلقية غير متجانسة لـmek وطرق استخدامها
CN101415689A (zh) 2006-04-05 2009-04-22 阿斯利康(瑞典)有限公司 具有抗癌活性的经取代的喹唑啉
EP2007737A2 (en) 2006-04-05 2008-12-31 AstraZeneca AB Chemical compounds
EP2010504A1 (en) * 2006-04-18 2009-01-07 AstraZeneca AB Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CA2855243C (en) 2011-11-11 2020-04-14 Novartis Ag Method of treating a proliferative disease
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
AU2017204973A1 (en) 2016-01-06 2018-07-12 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as EGFR inhibitors
WO2018115380A1 (en) 2016-12-22 2018-06-28 Boehringer Ingelheim International Gmbh Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
CN111247152B (zh) * 2017-09-20 2024-07-16 璧辰医药技术股份有限公司 作为激酶抑制剂的环状亚氨基嘧啶衍生物
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
CN113711012A (zh) 2018-09-14 2021-11-26 联合利华知识产权控股有限公司 免洗型化妆品组合物保护皮肤免受污染的功效的评估
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
TWI817018B (zh) 2023-10-01
JP7169469B2 (ja) 2022-11-10
CN114026073A (zh) 2022-02-08
MA56387A (fr) 2022-05-04
US11634409B2 (en) 2023-04-25
AU2020302352A1 (en) 2022-01-20
CA3144859C (en) 2023-09-12
US11414404B2 (en) 2022-08-16
WO2020261156A1 (en) 2020-12-30
US20220289721A1 (en) 2022-09-15
KR20220011712A (ko) 2022-01-28
JP2022539056A (ja) 2022-09-07
CO2021017438A2 (es) 2022-01-17
CN114026073B (zh) 2024-08-23
CU20210098A7 (es) 2022-06-06
EP3990437A1 (en) 2022-05-04
KR102712548B1 (ko) 2024-09-30
IL288214A (en) 2022-01-01
US20200407344A1 (en) 2020-12-31
CA3144859A1 (en) 2020-12-30
ZA202201329B (en) 2023-09-27
AU2020302352B2 (en) 2023-03-23
BR112021025102A2 (pt) 2022-01-25
ECSP21093541A (es) 2022-01-31
PE20220341A1 (es) 2022-03-14
MX2021015903A (es) 2022-02-03
IL288214B1 (en) 2024-11-01
TW202114996A (zh) 2021-04-16
CR20210626A (es) 2022-02-08

Similar Documents

Publication Publication Date Title
UY38767A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
CY1123936T1 (el) Μεθοδος παρασκευης παραγωγών οξαζολο[4,5-β]πυριδινης και θειαζολο[4,5-β]πυριδινης ως αναστολεων irak4 για την αγωγη του καρκινου
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
ZA202301672B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
CY1120702T1 (el) Μακροκυκλοι με ετεροκυκλικες ομαδες ρ2' ως αναστολεις τελεστη χια
WO2016105528A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
PH12016501935A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
AR113909A1 (es) Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b
NI201700174A (es) Derivados de amidas policíclicas como inhibidores de cdk
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
WO2016160617A3 (en) Inhibitors of cyclin-dependent kinases
UY37900A (es) Nuevos derivados de rapamicina
DOP2022000282A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
CY1120325T1 (el) Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης
PH12020551359A1 (en) Piperidinyl-3- (aryloxy) propanamides and propanoates
EA202191519A1 (ru) Модуляторы trex1
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CO2019011967A2 (es) Compuestos antitumorales
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
AR050297A1 (es) Hidantoinas sustituidas
MX2019011517A (es) Proceso para producir analogos de anillo de arilomicina.